Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 12/20 | 0.70 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.58 |
| ▸ | PGR | P06401 | 5/20 | 0.58 |
| ▸ | SMO | Q99835 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135413 | 0.89 | CYP11B2 (0.71) | CYP11B2NR3C1CYP11B1PGR | |
| SCHEMBL15839046 | 0.84 | CYP11B2 (1.00) | CYP11B2NR3C1CYP11B1PGRSMO | |
| SCHEMBL15839177 | 0.82 | CYP11B2 (0.70) | CYP11B2NR3C1CYP11B1PGR | |
| SCHEMBL22199134 | 0.81 | NR3C1 (0.57) | CYP11B2NR3C1CYP11B1PGRSMO | |
| SCHEMBL15839047 | 0.80 | CYP11B2 (1.00) | CYP11B2NR3C1CYP11B1PGR | |
| SCHEMBL839102 | 0.79 | NR3C1 (0.54) | CYP11B2NR3C1PGRSMO | |
| SCHEMBL21295429 | 0.79 | NR3C1 (0.54) | CYP11B2NR3C1PGRSMO | |
| SCHEMBL30127430 | 0.79 | NR3C1 (0.54) | CYP11B2NR3C1PGRSMO | |
| SCHEMBL29496849 | 0.79 | NR3C1 (0.65) | CYP11B2NR3C1PGRSMO | |
| SCHEMBL1135795 | 0.79 | NR3C1 (0.65) | CYP11B2NR3C1PGRSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | CYP11B2 3663/4885NR3C1 4497/4885CYP11B1 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.